Trials / Completed
CompletedNCT01068353
Safety and Tolerability of Etanercept in Alzheimer's Disease
A Phase 2, Double-blind, Placebo-controlled Study of the Safety and Tolerability of Etanercept in Patients With Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- University of Southampton · Academic / Other
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
The primary aim of the study is to determine the safety and tolerability of etanercept in subjects with Alzheimer's Disease. The effects of etanercept on cognitive, behavioural, functional and immunological outcomes will be examined as secondary aims.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Etanercept | 50 mg given as a once weekly subcutaneous injection |
| OTHER | Placebo | Placebo injection given once weekly |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2013-12-01
- First posted
- 2010-02-12
- Last updated
- 2014-04-23
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01068353. Inclusion in this directory is not an endorsement.